All In Biotech

Drug Trial Radar · NCT04476043

To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Last checked: Nov 20, 2026Latest source record: Aug 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 209 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

209

Actual

Start

Aug 25, 2020

Primary completion

Dec 15, 2021

Study completion Aug 16, 2023

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Jul 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of INCB054707 in participants with hidradenitis suppurativa over a 16-week placebo-controlled treatment period followed by a 36-week open-label extension period. All eligible participants will be invited to continue treatment for an additional 48-week Long-term extension period (also open label).

Conditions

  • Hidradenitis Suppurativa
  • Acne Inversa

Interventions

  • INCB054707Drug

    Oral; Tablet

  • PlaceboDrug

    Oral; Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16Time frame: Baseline; Week 16

Locations

40 sites in 6 countries. Site status is shown where the registry gives one.

  • Investigative Site 005

    Hoover, Alabama

  • Investigative Site 003

    Gilbert, Arizona

  • Investigative Site 011

    Phoenix, Arizona

  • Investigative Site 014

    Fountain Valley, California

  • Investigative Site 010

    Fremont, California

  • Investigative Site 012

    Huntington Beach, California

  • Investigative Site 022

    Newbury Park, California

  • Investigative Site 009

    Sacramento, California

  • Investigative Site 025

    Cromwell, Connecticut

  • Investigative Site 015

    Coral Gables, Florida

  • Investigative Site 021

    Miami, Florida

  • Investigative Site 006

    Tampa, Florida

  • Investigative Site 001

    Tampa, Florida

  • Investigative Site 016

    Atlanta, Georgia

  • Investigative Site 002

    West Lafayette, Indiana

  • Investigative Site 027

    Baton Rouge, Louisiana

  • Investigative Site 023

    New Orleans, Louisiana

  • Investigative Site 013

    Boston, Massachusetts

  • Investigative Site 004

    Fort Gratiot, Michigan

  • Investigative Site 019

    St Louis, Missouri

  • Investigative Site 026

    The Bronx, New York

  • Investigative Site 008

    Chapel Hill, North Carolina

  • Investigative Site 017

    Winston-Salem, North Carolina

  • Investigative Site 007

    Hershey, Pennsylvania

  • Investigative Site 018

    Bellaire, Texas

  • Investigative Site 101

    Calgary, Alberta, Canada

  • Investigative Site 102

    Calgary, Alberta, Canada

  • Investigative Site 304

    Nantes, France

  • Investigative Site 403

    Berlin, Germany

  • Investigative Site 401

    Bochum, Germany

  • Investigative Site 405

    Dessau, Germany

  • Investigative Site 406

    Dresden, Germany

  • Investigative Site 404

    Erlangen, Germany

  • Investigative Site 402

    Frankfurt am Main, Germany

  • Investigative Site 552

    Rzeszów, Poland

  • Investigative Site 551

    Wroclaw, Poland

  • Investigative Site 553

    Wroclaw, Poland

  • Investigative Site 703

    Granada, Spain

  • Investigative Site 702

    Madrid, Spain

  • Investigative Site 701

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.